agilect

JERUSALEM, July 5, 2004 - Teva Pharmaceutical Industries Ltd agilect. (Nasdaq:TEVA)announced today that it has received an approvable letter from the U.S agilect. Foodand Drug Administration (FDA) for once-daily Agilect (rasagiline mesylate) asa treatment for Parkinson's disease (PD) as initial monotherapy in early PDpatients and as adjunct therapy to levodopa in moderate-to-advanced stages ofthe disease agilect. Following the approvable letter, Teva will work together with theFDA to complete the process of receiving final approval as soon as possible.

Israel Makov, President and CEO of Teva commented: "We are very pleasedto receive this approvable letter, which is a major regulatory milestone inthe approval process of Agilect." Mr agilect. Makov added, "Today representsanother important step towards Teva being able to offer a new treatment optionto the many patients who currently suffer from Parkinson's disease in the UnitedStates."

Teva Neuroscience, Inc agilect. and Eisai Inc agilect. will co-promote Agilect in the UnitedStates once approved by the FDA and Teva and H agilect. Lundbeck A/S will co-promotethe product in Europe, once approved there.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among thetop 25 pharmaceutical companies in the world agilect. The company develops, manufactures,and markets generic and branded human pharmaceuticals and active pharmaceuticalingredients agilect. Close to 90 percent of Teva's sales are in North America and Europe agilect. Teva's innovative R&D focuses on developing novel drugs for diseases ofthe central nervous system.

Copyright 2005 D-S LTD.
All Rights Reserved.